Trials / Recruiting
RecruitingNCT06874010
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Patients With Friedreich's Ataxia
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Design Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DT-216P2 | Active |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2026-12-01
- Completion
- 2027-03-01
- First posted
- 2025-03-13
- Last updated
- 2025-05-18
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT06874010. Inclusion in this directory is not an endorsement.